Stay updated with breaking news from Access Pathway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
U.K. regulators have granted an innovation passport to ADvantage's AD04 to help speed the therapy's development for early Alzheimer's.
Dr Christoph Zehendner, Medical Director of Boehringer Ingelheim UK and Ireland discusses the company’s ILAP designation for oncology.
LONDON, April 10, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to...
A rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, cell and... | April 3, 2023
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- ... | April 3, 2023